Catalyst is a clinical-stage biopharmaceutical company leveraging exceptional science to discover an
Location: United States, California, South San Francisco
Employees: 51-200
Phone: 650-871-0761
Total raised: $90M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Auriga Par... | auriga.vc |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| - | Avoro Capi... | avorocapit... |
| - | Sofinnova ... | sofinnova.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.01.2021 | - | $50M | - |
| 04.12.2008 | Series C | $40M | - |
Mentions in press and media 16
| Date | Title | Description |
| 27.05.2022 | Transition to new European clinical trials info system starts slowly | As the close runner-up to Amgen’s Lumakras in the KRAS race, any data cut from Mirati’s adagrasib continues to draw scrutiny from analysts. And the latest batch of numbers from ASCO is a decidedly mixed bag. While a quick comparison suggest... |
| 27.05.2022 | Transition to new European clinical trials info system starts slowly | Catalyst Biosciences was down to five employees in March, and the biotech needed to do something after two rounds of layoffs, a nixed collaboration and a culling of its hemophilia program. In came Vertex, with $60 million to buy up the Sout... |
| 27.05.2022 | EU reportedly eyeing vaccines deal for monkeypox outbreak; Nasdaq tells Mereo to get stock price up or face delisting | The EU is reportedly working toward a centralized procurement deal for smallpox vaccines to tackle the rising number of cases of monkeypox, according to sources who spoke to the Financial Times. Andrea Ammon, direct... |
| 27.05.2022 | Transition to new European clinical trials info system starts slowly | Before cancer-focused biotechs start their trek to the first in-person American Society of Clinical Oncology (ASCO) annual conference since the pandemic began, investors have taken a good look at the teasers for the data scheduled to be pre... |
| 27.05.2022 | Transition to new European clinical trials info system starts slowly | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 27.05.2022 | Covid-19 roundup: CDC study shows good protection from mRNA booster plus J&J's single-dose vaccine; White House launches test-to-treat Paxlovid site | Concerns about rare but life-threatening blood clots have limited the use of J&J’s Covid-19 vaccine — once pitched as the only one-shot option in the mix — with the FDA cutting it off except in limited circumstances. Yet t... |
| 26.05.2022 | HHS finishes off Trump-era rule that would've erased basic FDA regs without frequent reviews | The Senate is joining its House counterparts and advancing accelerated approval pathway reforms to the FDA user fee legislation that must be signed by President Joe Biden before the end of September or else the FDA will have to start laying... |
| 12.01.2022 | Catalyst Biosciences : Investor presentation 5.9 MB | CATALYST BIOSCIENCES Corporate Overview 12 January 2022 Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substa... |
| 15.11.2021 | Catalyst Biosciences : Investor presentation 4.7 MB | CATALYST BIOSCIENCES Corporate Overview 15 November 2021 © Catalyst Biosciences Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statem... |
| 28.09.2021 | Catalyst Biosciences : Investor presentation 3.1 MB | Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 28 September 2021 CatalystBiosciences.com Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward... |
Show more